TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting

BACKGROUND: We investigated the impact of PIK3CA and TP53 mutations and p53 protein status on the outcome of patients who had been treated with adjuvant anthracycline-taxane chemotherapy within clinical trials in the pre- and post-trastuzumab era. RESULTS: TP53 and PIK3CA mutations were found in 380...

Descripción completa

Detalles Bibliográficos
Autores principales: Fountzilas, George, Giannoulatou, Eleni, Alexopoulou, Zoi, Zagouri, Flora, Timotheadou, Eleni, Papadopoulou, Kyriaki, Lakis, Sotiris, Bobos, Mattheos, Poulios, Christos, Sotiropoulou, Maria, Lyberopoulou, Aggeliki, Gogas, Helen, Pentheroudakis, George, Pectasides, Dimitrios, Koutras, Angelos, Christodoulou, Christos, Papandreou, Christos, Samantas, Epaminontas, Papakostas, Pavlos, Kosmidis, Paris, Bafaloukos, Dimitrios, Karanikiotis, Charisios, Dimopoulos, Meletios-Athanassios, Kotoula, Vassiliki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078047/
https://www.ncbi.nlm.nih.gov/pubmed/27129168
http://dx.doi.org/10.18632/oncotarget.9022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078047/
https://www.ncbi.nlm.nih.gov/pubmed/27129168
http://dx.doi.org/10.18632/oncotarget.9022

Ejemplares similares